$CDNA
CareDx, Inc.

2019 Q2 Form 10-Q Financial Statement

#000156459019028018 Filed on August 01, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q4 2018 Q2
Revenue $31.45M $23.51M $17.82M
YoY Change 76.48% 88.03% 47.96%
Cost Of Revenue $11.51M $10.51M $7.207M
YoY Change 59.73% 88.01% 38.86%
Gross Profit $19.94M $13.00M $10.62M
YoY Change 87.85% 88.13% 54.75%
Gross Profit Margin 63.4% 55.3% 59.56%
Selling, General & Admin $19.16M $11.63M $11.46M
YoY Change 67.16% 59.32% 54.86%
% of Gross Profit 96.06% 89.46% 107.95%
Research & Development $7.630M $3.780M $3.496M
YoY Change 118.25% 24.75% 12.05%
% of Gross Profit 38.26% 29.08% 32.93%
Depreciation & Amortization $1.220M $1.180M $990.0K
YoY Change 23.23% 15.69% 11.24%
% of Gross Profit 6.12% 9.08% 9.33%
Operating Expenses $26.79M $15.41M $15.83M
YoY Change 69.26% 37.59% 1.15%
Operating Profit -$6.844M -$2.410M -$5.209M
YoY Change 31.39% -43.82% 44.73%
Interest Expense $300.0K $1.390M -$424.0K
YoY Change -170.75% -104.98% -74.93%
% of Operating Profit
Other Income/Expense, Net -$1.223M $2.710M -$9.234M
YoY Change -86.76% -1003.33% 4811.7%
Pretax Income -$8.067M -$4.090M -$14.44M
YoY Change -44.15% -87.42% 227.43%
Income Tax -$200.0K -$340.0K -$381.0K
% Of Pretax Income
Net Earnings -$7.847M -$3.755M -$14.06M
YoY Change -44.2% -88.14% 254.39%
Net Earnings / Revenue -24.95% -15.97% -78.9%
Basic Earnings Per Share -$0.19 -$0.09 -$0.40
Diluted Earnings Per Share -$0.19 -$0.09 -$0.40
COMMON SHARES
Basic Shares Outstanding 42.13M shares 40.10M shares 35.55M shares
Diluted Shares Outstanding 42.13M shares 40.10M shares 35.55M shares

Balance Sheet

Concept 2019 Q2 2018 Q4 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.50M $64.60M $16.20M
YoY Change 168.52% 282.25% 78.02%
Cash & Equivalents $43.47M $64.62M $16.25M
Short-Term Investments
Other Short-Term Assets $2.500M $1.800M $1.600M
YoY Change 56.25% 28.57% 6.67%
Inventory $5.341M $4.943M $4.666M
Prepaid Expenses
Receivables $17.05M $9.760M $8.072M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $68.32M $81.11M $30.58M
YoY Change 123.45% 203.04% 53.65%
LONG-TERM ASSETS
Property, Plant & Equipment $3.508M $4.134M $2.360M
YoY Change 48.64% 99.23% -5.6%
Goodwill $10.20M $12.01M $12.01M
YoY Change -15.04% 0.0%
Intangibles $45.60M $33.25M $34.76M
YoY Change 31.2% 0.34%
Long-Term Investments
YoY Change
Other Assets $300.0K $0.00 $200.0K
YoY Change 50.0% -100.0% -97.92%
Total Long-Term Assets $74.58M $49.58M $49.30M
YoY Change 51.28% -12.7% -14.76%
TOTAL ASSETS
Total Short-Term Assets $68.32M $81.11M $30.58M
Total Long-Term Assets $74.58M $49.58M $49.30M
Total Assets $142.9M $130.7M $79.88M
YoY Change 78.9% 56.4% 2.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.380M $4.711M $3.480M
YoY Change 112.07% 38.93% -3.33%
Accrued Expenses $12.80M $11.20M $6.700M
YoY Change 91.04% 28.74% -22.99%
Deferred Revenue $39.00K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $28.60M $19.50M $14.18M
YoY Change 101.75% -54.54% -73.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $13.34M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $18.80M $2.294M $19.70M
YoY Change -4.57% 74.45% 1360.34%
Total Long-Term Liabilities $0.00 $2.294M $13.34M
YoY Change -100.0% -88.33% 888.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.60M $19.50M $14.18M
Total Long-Term Liabilities $0.00 $2.294M $13.34M
Total Liabilities $49.70M $34.77M $27.51M
YoY Change 80.64% -61.16% -58.16%
SHAREHOLDERS EQUITY
Retained Earnings -$311.8M -$288.1M
YoY Change 16.35% 29.74%
Common Stock $425.4M $412.1M $321.1M
YoY Change 32.47% 55.94% 35.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $93.17M $95.93M $28.95M
YoY Change
Total Liabilities & Shareholders Equity $142.9M $130.7M $79.88M
YoY Change 78.9% 56.4% 2.75%

Cashflow Statement

Concept 2019 Q2 2018 Q4 2018 Q2
OPERATING ACTIVITIES
Net Income -$7.847M -$3.755M -$14.06M
YoY Change -44.2% -88.14% 254.39%
Depreciation, Depletion And Amortization $1.220M $1.180M $990.0K
YoY Change 23.23% 15.69% 11.24%
Cash From Operating Activities $3.580M $2.000M -$1.880M
YoY Change -290.43% -193.02% -41.25%
INVESTING ACTIVITIES
Capital Expenditures -$1.150M -$960.0K -$5.600M
YoY Change -79.46% 966.67% 27900.0%
Acquisitions
YoY Change
Other Investing Activities -$16.04M $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$17.18M -$960.0K -$5.610M
YoY Change 206.24% -80.95% 27950.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -270.0K 37.31M 5.080M
YoY Change -105.31% 108.2% 2209.09%
NET CHANGE
Cash From Operating Activities 3.580M 2.000M -1.880M
Cash From Investing Activities -17.18M -960.0K -5.610M
Cash From Financing Activities -270.0K 37.31M 5.080M
Net Change In Cash -13.87M 38.35M -2.410M
YoY Change 475.52% 257.41% -19.67%
FREE CASH FLOW
Cash From Operating Activities $3.580M $2.000M -$1.880M
Capital Expenditures -$1.150M -$960.0K -$5.600M
Free Cash Flow $4.730M $2.960M $3.720M
YoY Change 27.15% -243.69% -216.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Shell Company
EntityShellCompany
false
dei Entity Address State Or Province
EntityAddressStateOrProvince
California
dei Entity Address Country
EntityAddressCountry
US
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42383761
dei Entity File Number
EntityFileNumber
001-36536
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
943316839
dei Entity Address Address Line1
EntityAddressAddressLine1
3260 Bayshore Boulevard
dei Entity Address City Or Town
EntityAddressCityOrTown
Brisbane
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94005
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
287-2300
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43469000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64616000
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17052000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9760000
CY2019Q2 us-gaap Inventory Net
InventoryNet
5341000
CY2018Q4 us-gaap Inventory Net
InventoryNet
4943000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2462000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1795000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
68324000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
81114000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3508000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2025000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4134000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2657000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
45604000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
33252000
CY2019Q2 us-gaap Goodwill
Goodwill
22559000
CY2018Q4 us-gaap Goodwill
Goodwill
12005000
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
255000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
192000
CY2019Q2 us-gaap Assets
Assets
142907000
CY2018Q4 us-gaap Assets
Assets
130697000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7380000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4711000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7490000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9156000
CY2019Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13750000
CY2018Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5637000
CY2019Q2 cdna Deferred Payments For Intangible Assets Noncurrent
DeferredPaymentsForIntangibleAssetsNoncurrent
4930000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
425418000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
142907000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
130697000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 cdna Deferred Payments For Intangible Assets Noncurrent
DeferredPaymentsForIntangibleAssetsNoncurrent
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42306432
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41384960
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42306432
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41384960
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31454000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17823000
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
11512000
CY2018Q2 us-gaap Cost Of Revenue
CostOfRevenue
7207000
us-gaap Cost Of Revenue
CostOfRevenue
21245000
us-gaap Cost Of Revenue
CostOfRevenue
13591000
CY2019Q2 us-gaap Gross Profit
GrossProfit
19942000
CY2018Q2 us-gaap Gross Profit
GrossProfit
10616000
us-gaap Gross Profit
GrossProfit
36191000
us-gaap Gross Profit
GrossProfit
18285000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7630000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3496000
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10644000
CY2018Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5860000
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
300000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13417000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8512000
CY2019Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2018Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
873000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
26786000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
15825000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6844000
cdna Extinguishment Of Debt And Conversion Of Debt To Equity Expenses
ExtinguishmentOfDebtAndConversionOfDebtToEquityExpenses
2806000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1223000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9234000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3964000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
95928000
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
341000
CY2019Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-2378000
CY2019Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
51000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1365000
CY2019Q1 cdna Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value
IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue
2569000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6001000
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-724000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-7531000
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
95622000
CY2019Q2 cdna Adjustments To Additional Paid In Capital Changes In Estimated Offering Costs
AdjustmentsToAdditionalPaidInCapitalChangesInEstimatedOfferingCosts
50000
CY2019Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-1597000
CY2019Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
52000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1405000
CY2019Q2 cdna Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value
IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue
612000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4938000
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
93166000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5955000
CY2018Q1 cdna Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity
6550000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
38854000
CY2018Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
32000
CY2018Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-128000
CY2018Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
62000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
80000
CY2018Q1 cdna Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value
IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue
153000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
634000
CY2018Q1 cdna Noncontrolling Interest Increase Decrease From Business Combination
NoncontrollingInterestIncreaseDecreaseFromBusinessCombination
-692000
CY2018Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-137000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-8994000
CY2018Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
33392000
CY2018Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-570000
CY2018Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
72000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
98000
CY2018Q2 cdna Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value
IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue
5724000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2449000
CY2018Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
2690000
CY2018Q2 cdna Issuance Of Warrants In Connection With Perceptive Debt
IssuanceOfWarrantsInConnectionWithPerceptiveDebt
784000
CY2018Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
28952000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2380000
cdna Loss On Write Off Of Fixed Assets
LossOnWriteOffOfFixedAssets
150000
cdna Loss On Write Off Of Fixed Assets
LossOnWriteOffOfFixedAssets
0
us-gaap Operating Lease Expense
OperatingLeaseExpense
201000
us-gaap Operating Lease Expense
OperatingLeaseExpense
0
us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
0
us-gaap Cost Of Goods And Services Sold Depreciation
CostOfGoodsAndServicesSoldDepreciation
189000
cdna Loss On Conversion Of Debt To Shares Of Common Stock
LossOnConversionOfDebtToSharesOfCommonStock
0
cdna Loss On Conversion Of Debt To Shares Of Common Stock
LossOnConversionOfDebtToSharesOfCommonStock
2806000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2132000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5956000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2280000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-333000
cdna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-418000
cdna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
195000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1208000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
73000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
517000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
892000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2291000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6404000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
16037000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1124000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5202000
cdna Payments To Acquire Businesses And Noncontrolling Interest
PaymentsToAcquireBusinessesAndNoncontrollingInterest
0
cdna Payments To Acquire Businesses And Noncontrolling Interest
PaymentsToAcquireBusinessesAndNoncontrollingInterest
692000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17722000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6355000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
341000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
32000
cdna Taxes Paid Related To Net Share Settlement Of Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits
3975000
cdna Taxes Paid Related To Net Share Settlement Of Restricted Stock Units
TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits
142000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
105000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
524000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2769000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
179000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
84000
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
0
us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-677000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-960000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2758000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-111000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-50000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21084000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10051000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64808000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26474000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43724000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16423000
cdna Deferred Payments For Acquired Intangible Assets
DeferredPaymentsForAcquiredIntangibleAssets
6954000
cdna Deferred Payments For Acquired Intangible Assets
DeferredPaymentsForAcquiredIntangibleAssets
0
cdna Operating Leases Right Of Use Assets Of Cash Flow Information
OperatingLeasesRightOfUseAssetsOfCashFlowInformation
2657000
cdna Operating Leases Right Of Use Assets Of Cash Flow Information
OperatingLeasesRightOfUseAssetsOfCashFlowInformation
0
cdna Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
111000
cdna Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
0
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Reclassifications and Changes in Presentation</font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain prior period amounts have been reclassified to conform with the current period presentation, including: (i) separate presentation of debt extinguishment expenses from other expense, net, (ii) combined presentation of license and other revenue with digital revenue, (iii) combined presentation of cost of testing services and cost of product, and (iv) separate presentation of gross profit. These reclassifications had no effect on the reported results of operations.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Use of Estimates</font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes.&nbsp;&nbsp;On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; standalone fair value of digital revenue performance obligations; accrued expenses for clinical studies;&#160;inventory valuation; the fair value of issued common stock warrants and embedded derivatives;&#160;the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired);&#160;the fair value of contingent consideration recorded in connection with a business combination; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies.&nbsp;&nbsp;Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Concentrations of Credit Risk and Other Risks and Uncertainties</font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the six months ended June 30, 2019 and 2018, approximately 54% and 45%, respectively, of total revenue was derived from Medicare.<font style="color:#000000;"> No other payers or customers represented more than 10% of total revenue for these periods.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2019 and December 31, 2018, approximately 27% and 27%, respectively, of accounts receivable was due from Medicare.&nbsp;&nbsp;No other payer or customer represented more than 10% of accounts receivable on either June 30, 2019 or December&#160;31, 2018. </p>
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42132396
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35549837
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41873337
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32599032
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2019Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8695000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7143000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4464528
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6786451
cdna Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2018 cdna Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2019Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets
200000
CY2019Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
200000
CY2019Q2 us-gaap Finite Lived Intangible Assets Fair Value Disclosure
FiniteLivedIntangibleAssetsFairValueDisclosure
6600000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
10554000
CY2019Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
52934000
CY2019Q2 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
3457000
CY2019Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
40782000
CY2019Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
57756000
CY2019Q2 cdna Intangible Assets Excluding Goodwill Accumulated Amortization
IntangibleAssetsExcludingGoodwillAccumulatedAmortization
8695000
CY2019Q2 cdna Intangible Assets Excluding Goodwill Foreign Currency Translation Gain Loss
IntangibleAssetsExcludingGoodwillForeignCurrencyTranslationGainLoss
-3457000
CY2018Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
38255000
CY2018Q4 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
2682000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28430000
CY2018Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
43077000
CY2018Q4 cdna Intangible Assets Excluding Goodwill Accumulated Amortization
IntangibleAssetsExcludingGoodwillAccumulatedAmortization
7143000
CY2018Q4 cdna Intangible Assets Excluding Goodwill Foreign Currency Translation Gain Loss
IntangibleAssetsExcludingGoodwillForeignCurrencyTranslationGainLoss
-2682000
CY2019Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
700000
CY2018Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1200000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2079000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4291000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4054000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
4037000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
4037000
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
22284000
CY2019Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2519000
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2506000
CY2019Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
940000
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
651000
CY2019Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1882000
CY2018Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1786000
CY2019Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3624000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
39000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2034000
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2019Q2 cdna Deferred Payments For Intangible Assets
DeferredPaymentsForIntangibleAssets
2000000
CY2018Q4 cdna Deferred Payments For Intangible Assets
DeferredPaymentsForIntangibleAssets
0
CY2019Q2 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
1993000
CY2018Q4 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
1815000
CY2019Q2 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
782000
CY2018Q4 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
657000
CY2019Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
696000
CY2018Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
285000
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
596000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
822000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2025000
us-gaap Operating Lease Cost
OperatingLeaseCost
905000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2019000
cdna Leases Expiration Period
LeasesExpirationPeriod
2022
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
455000
CY2019Q2 cdna Finance Lease Cost
FinanceLeaseCost
55000
CY2019Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
cdna Finance Lease Cost
FinanceLeaseCost
110000
CY2019Q2 us-gaap Lease Cost
LeaseCost
510000
us-gaap Lease Cost
LeaseCost
1015000
CY2019Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
385000
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2019Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105
CY2019Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.065
CY2019Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000
CY2018Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900000
CY2019Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
105000
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
209000
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
71000
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1140000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2310000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
223000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
97000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3770000
CY2019Q2 us-gaap Payments For Royalties
PaymentsForRoyalties
300000
us-gaap Payments For Royalties
PaymentsForRoyalties
400000
CY2019Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2018Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2019Q2 cdna Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
24000
cdna Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
94000
CY2018Q2 cdna Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
445000
cdna Purchase Of Common Stock Warrants Exercised
PurchaseOfCommonStockWarrantsExercised
468000
CY2018Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
500000
CY2019Q2 cdna Exercise Of Warrants Shares
ExerciseOfWarrantsShares
40000
cdna Exercise Of Warrants Shares
ExerciseOfWarrantsShares
96000
CY2019Q2 cdna Shares Issued Upon Exercise Of Warrants Shares
SharesIssuedUponExerciseOfWarrantsShares
15000
cdna Shares Issued Upon Exercise Of Warrants Shares
SharesIssuedUponExerciseOfWarrantsShares
40000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
322178
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
1655398
cdna Share Based Compensation Arrangement By Share Based Payment Award Common Stock Awards For Services
ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices
3626
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
831860
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod
0
cdna Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans
ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans
133913
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
93185
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
134504
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1439
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
648166
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2501057
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Acquisitions In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromAcquisitionsInPeriod
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
491581
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2705393
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.10
cdna Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
28.11
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.64
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.76
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
15.44
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2584856
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.86
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
12000000
CY2019Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
903539
CY2019Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
1681317
CY2019Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
19.97
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
P6Y7M20D
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P9Y2M19D
CY2019Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
26697000
CY2019Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
26984000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
53681000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4992000
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2512000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11045000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3217000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2018 cdna Tax Cuts And Jobs Act Of2017 Global Intangible Low Taxed Income Tax Rate
TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeTaxRate
0.105
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1

Files In Submission

Name View Source Status
0001564590-19-028018-index-headers.html Edgar Link pending
0001564590-19-028018-index.html Edgar Link pending
0001564590-19-028018.txt Edgar Link pending
0001564590-19-028018-xbrl.zip Edgar Link pending
cdna-10q_20190630.htm Edgar Link pending
cdna-20190630.xml Edgar Link completed
cdna-20190630.xsd Edgar Link pending
cdna-20190630_cal.xml Edgar Link unprocessable
cdna-20190630_def.xml Edgar Link unprocessable
cdna-20190630_lab.xml Edgar Link unprocessable
cdna-20190630_pre.xml Edgar Link unprocessable
cdna-ex311_6.htm Edgar Link pending
cdna-ex312_8.htm Edgar Link pending
cdna-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending